Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

BEDFORD, Mass., Feb. 13, 2024 -- Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and...

Related Keywords

United States ,California ,Ben Shannon ,Chris Brinzey ,Dilsher Dhoot ,Donald Notman ,Antony Mattessich ,Retinal Pharmaceuticals Market ,Globenewswire Inc ,Exchange Commission ,Ocular Therapeutix Inc ,Nasdaq ,Special Protocol Assessment ,Agreement Modification ,Ocular Therapeutix ,Valley Retina ,Retinal Pharmaceuticals Market Report ,Private Securities Litigation Reform Act ,Markets ,